Implications of Mid-Study Clinical Trial Protocol Changes


Medidata & Tufts Center for the Study of Drug Development announced results of a study on the impact of protocol amendmends made while a clinical trial is underway. The study discussed their avoidability, costs and time delays.

Read the full release here

Read more in Kenneth Getz’s column this month here

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Related Content
© 2024 MJH Life Sciences

All rights reserved.